BNTX – BioNTech SE
Float Short %
2.08
Margin Of Safety %
Put/Call OI Ratio
0.45
EPS Next Q Diff
-1.88
EPS Last/This Y
-0.2
EPS This/Next Y
1.18
Price
110.1
Target Price
141.68
Analyst Recom
1.43
Performance Q
7.43
Upside
-183.6%
Beta
1.51
Ticker: BNTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | BNTX | 116.1 | 0.45 | 0.67 | 35468 |
| 2026-01-26 | BNTX | 117.62 | 0.46 | 0.71 | 35839 |
| 2026-01-27 | BNTX | 119.25 | 0.46 | 0.33 | 36312 |
| 2026-01-28 | BNTX | 116.04 | 0.45 | 0.75 | 36733 |
| 2026-01-29 | BNTX | 116.81 | 0.45 | 0.43 | 36934 |
| 2026-01-30 | BNTX | 113.75 | 0.45 | 0.97 | 37018 |
| 2026-02-02 | BNTX | 108.94 | 0.45 | 0.85 | 37063 |
| 2026-02-03 | BNTX | 108.28 | 0.46 | 0.47 | 37251 |
| 2026-02-05 | BNTX | 105.64 | 0.47 | 1.24 | 37766 |
| 2026-02-09 | BNTX | 110.47 | 0.47 | 0.29 | 37913 |
| 2026-02-10 | BNTX | 108.97 | 0.47 | 0.29 | 37979 |
| 2026-02-11 | BNTX | 109.44 | 0.47 | 1.19 | 38076 |
| 2026-02-12 | BNTX | 105.68 | 0.47 | 0.15 | 38173 |
| 2026-02-13 | BNTX | 105.81 | 0.47 | 2.93 | 38439 |
| 2026-02-17 | BNTX | 107.01 | 0.47 | 0.05 | 38489 |
| 2026-02-18 | BNTX | 107.97 | 0.47 | 0.11 | 38609 |
| 2026-02-19 | BNTX | 110.43 | 0.46 | 0.19 | 38651 |
| 2026-02-20 | BNTX | 110.14 | 0.45 | 1.25 | 39234 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | BNTX | 115.87 | -105.5 | -877.7 | -3.42 |
| 2026-01-26 | BNTX | 117.99 | -105.8 | -996.2 | -3.42 |
| 2026-01-27 | BNTX | 119.25 | -105.8 | -990.3 | -3.42 |
| 2026-01-28 | BNTX | 116.01 | -105.0 | -887.2 | -3.42 |
| 2026-01-29 | BNTX | 116.80 | -105.0 | -947.3 | -3.42 |
| 2026-01-30 | BNTX | 113.82 | -105.0 | -855.2 | -3.42 |
| 2026-02-02 | BNTX | 108.89 | -105.0 | -800.0 | -3.42 |
| 2026-02-03 | BNTX | 108.25 | -109.0 | -888.6 | -3.42 |
| 2026-02-04 | BNTX | 108.85 | -109.0 | -945.4 | -3.42 |
| 2026-02-05 | BNTX | 105.58 | -108.0 | -840.6 | -3.42 |
| 2026-02-06 | BNTX | 106.62 | -108.0 | -963.1 | -3.42 |
| 2026-02-09 | BNTX | 110.35 | -108.0 | -1037.1 | -3.42 |
| 2026-02-10 | BNTX | 108.97 | -108.0 | -896.9 | -3.42 |
| 2026-02-11 | BNTX | 109.40 | -108.0 | -962.6 | -3.42 |
| 2026-02-12 | BNTX | 105.68 | -108.0 | -841.9 | -3.42 |
| 2026-02-13 | BNTX | 105.76 | -108.0 | -955.7 | -3.42 |
| 2026-02-17 | BNTX | 106.96 | -108.0 | -980.0 | -3.42 |
| 2026-02-18 | BNTX | 108.01 | -108.0 | -977.7 | -3.42 |
| 2026-02-19 | BNTX | 110.43 | -108.0 | -1019.6 | -3.42 |
| 2026-02-20 | BNTX | 110.10 | -108.0 | - | -3.42 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | BNTX | 0.00 | -1.88 | 2.08 |
| 2026-01-26 | BNTX | 0.00 | -1.75 | 2.08 |
| 2026-01-27 | BNTX | 0.00 | -1.75 | 2.08 |
| 2026-01-28 | BNTX | 0.00 | -1.75 | 2.03 |
| 2026-01-29 | BNTX | 0.00 | -1.75 | 2.03 |
| 2026-01-30 | BNTX | 0.00 | -1.75 | 2.03 |
| 2026-02-02 | BNTX | 0.00 | -6.30 | 2.03 |
| 2026-02-03 | BNTX | 0.00 | -6.30 | 2.03 |
| 2026-02-04 | BNTX | 0.00 | -6.30 | 2.03 |
| 2026-02-05 | BNTX | 0.00 | -6.30 | 2.03 |
| 2026-02-06 | BNTX | 0.00 | -6.30 | 2.03 |
| 2026-02-09 | BNTX | 0.00 | -6.67 | 2.03 |
| 2026-02-10 | BNTX | 0.00 | -6.67 | 2.03 |
| 2026-02-11 | BNTX | 0.00 | -6.67 | 2.09 |
| 2026-02-12 | BNTX | 0.00 | -6.67 | 2.09 |
| 2026-02-13 | BNTX | 0.00 | -6.67 | 2.09 |
| 2026-02-17 | BNTX | 0.00 | -5.28 | 2.08 |
| 2026-02-18 | BNTX | 0.00 | -5.28 | 2.08 |
| 2026-02-19 | BNTX | 0.00 | -5.28 | 2.08 |
| 2026-02-20 | BNTX | 0.00 | -5.28 | 2.08 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.14
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-2.02
Insider Transactions
Institutional Transactions
-5.28
Beta
1.51
Average Sales Estimate Current Quarter
823
Average Sales Estimate Next Quarter
316
Fair Value
Quality Score
57
Growth Score
35
Sentiment Score
73
Actual DrawDown %
76.3
Max Drawdown 5-Year %
-82.2
Target Price
141.68
P/E
Forward P/E
PEG
P/S
7.5
P/B
1.22
P/Free Cash Flow
EPS
-2.63
Average EPS Est. Cur. Y
-3.42
EPS Next Y. (Est.)
-2.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-17.91
Relative Volume
0.84
Return on Equity vs Sector %
-32.1
Return on Equity vs Industry %
-14.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
0.19
EBIT Estimation
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading